Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence (Q38819055)

6 September 2017

title

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence (English)

1 reference

6 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

1

Biagio Ricciuti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

7

Rita Chiari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

3

Giulio Metro

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

4

Sara Baglivo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Roberta Matocci

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

Matteo Pirro

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

publication date

25 April 2017

1 reference

6 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28444624 AND SRC:MED&resulttype=core&format=json

7 June 2020

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

TRKing down an old oncogene in a new era of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

The trk proto-oncogene encodes a receptor for nerve growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Trk receptor tyrosine kinases: a bridge between cancer and neural development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Trk receptors: roles in neuronal signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

The landscape of kinase fusions in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-017-0967-5

A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth

21 January 2018

1 reference

12 December 2020

Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro

1 reference

12 December 2020

The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation

1 reference

12 December 2020

1 reference

12 December 2020